Vertex Pharmaceuticals Inc

NASDAQ: VRTX
$404.91
+$4.99 (+1.2%)
Closing price April 23, 2024
Vertex Pharmaceuticals Inc is a pioneering biotechnology firm focused on creating innovative treatments for cystic fibrosis (CF) and other serious diseases. It offers a range of CF therapies, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting different age groups and genetic mutations. Beyond CF, Vertex is exploring treatments for pain, sickle cell disease, beta thalassemia, and Type 1 Diabetes through advanced clinical trials. Founded in 1989 and based in Boston, Massachusetts, Vertex collaborates with leading biotech entities to expand its therapeutic portfolio, aiming to address unmet medical needs.
Friday’s top analyst upgrades and downgrades included BP, Cloudflare, Expedia, FireEye, Marathon Oil, Moderna, Pinduoduo, Vertex Pharmaceuticals and ViacomCBS.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Acceleron Pharma, BioNTech, CyberArk Software, Five9 and Vertex Pharmaceuticals.
Thursday’s top analyst upgrades and downgrades included AutoNation, Enbridge, Gap, JinkoSolar, Micron Technology, Nvidia, Tractor Supply, Twilio and Vertex Pharmaceuticals.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Celsius, Nasdaq, SmartSheet, Twilio and Zoom Video.
Here are five notable health care laggard stocks that appear to have plenty of upside potential. Most of them are dividend payers too.
Wednesday's top analyst upgrades and downgrades included Applied Materials, Caterpillar, Costco Wholesale, JPMorgan, Spotify, Vertex Pharmaceutical, Vornado Realty Trust and Whiting Petroleum.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL, Salesforce.com, Slack Technologies and Wells Fargo.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
Thursday's top analyst upgrades and downgrades included Alkermes, Amazon.com, Citigroup, eBay, Fastly, Groupon, Lyft, Netflix, ONEOK, Roku, Uber Technologies and Zoom Video Communications.